EN | UA
EN | UA

Help Support

Back

Comparison of infliximab and standard treatment in children with moderate-to-severe Crohn’s disease

Comparison of infliximab and standard treatment in children with moderate-to-severe Crohn’s disease Comparison of infliximab and standard treatment in children with moderate-to-severe Crohn’s disease
Comparison of infliximab and standard treatment in children with moderate-to-severe Crohn’s disease Comparison of infliximab and standard treatment in children with moderate-to-severe Crohn’s disease

This study compared if beginning first-line infliximab (IFX) is more effective to accomplish and sustain remission than the standard treatment.

See All

Key take away

In case of failure of exclusive enteral nutrition, corticosteroid and immunomodulator therapies, the initiation of infliximab can be effective in paediatric patients diagnosed with moderate-to-severe Crohn’s disease recently.

Background

This study compared if beginning first-line infliximab (IFX) is more effective to accomplish and sustain remission than the standard treatment.

Method

Children aged 3–17 years (weighted Paediatric CD Activity Index score (wPCDAI) greater than 40) with newly diagnosed Crohn’s disease were included. They were allocated to groups to receive five infusions of IFX 5 mg/kg at specified weeks first-line IFX, or exclusive enteral nutrition or standard treatment as prednisolone given orally (1 mg/kg, maximum 40 mg). Primary outcome was clinical remission on azathioprine.

Result

On the whole, 100 patients were divided into first-line IFX group and standard group (50 patients in each). Four patients did not obtain treatment according to protocol. Many patients in the FL-IFX group achieved clinical and endoscopic remission as compared to standard treatment at week 10 (Table 1):


On the other hand, 19 patients in the first-line IFX group (out of 46 patients) were in clinical remission on azathioprine alone without the requirement of treatment escalation as opposed to 7 patients in the standard group (out of 48 patients).

Conclusion

The first-line IFX was found to be superior than standard treatment in attaining short-term clinical and endoscopic remission, with a higher probability of clinical remission maintenance at week 52 on azathioprine alone.

Source:

Gut

Article:

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Authors:

Maria M E Jongsma et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: